The CEO of Arqule is Exercising Options


Today it was reported that the CEO of Arqule (ARQL), Paolo Pucci, exercised options to buy 50,000 ARQL shares at $1.16 a share, for a total transaction value of $58K.

Following this transaction Paolo Pucci’s holding in the company was increased by 8.8% to a total of $2.89 million. Following Paolo Pucci’s last ARQL Buy transaction on May 18, 2018, the stock climbed by 1.3%.

See today’s analyst top recommended stocks >>

Based on Arqule’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $2.94 million and GAAP net loss of $8.49 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $7.76 million. Currently, Arqule has an average volume of 627K.

Starting in March 2018, ARQL received 23 Buy ratings in a row. Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $7.44, reflecting a 59.0% upside. Four different firms, including B.Riley FBR and Needham, currently also have a Buy rating on the stock.

Paolo Pucci’s trades have generated a 137.7% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts